The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 31, 2020

Filed:

Jan. 10, 2018
Applicant:

Probiodrug Ag, Halle (Saale), DE;

Inventors:

Martin Kleinschmidt, Halle, DE;

Jens-Ulrich Rahfeld, Gemeinde Seegebiet Mansfelder Land, DE;

Anke Piechotta, Halle, DE;

Stephan Schilling, Halle, DE;

Stephen Gillies, Carlisle, MA (US);

Assignee:

Probiodrug AG, Halle (Saale), DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61P 25/14 (2006.01); A61P 25/28 (2006.01); A61K 39/395 (2006.01); G01N 33/68 (2006.01); C07K 16/18 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0008 (2013.01); A61K 39/3955 (2013.01); A61P 25/14 (2018.01); A61P 25/28 (2018.01); C07K 16/18 (2013.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/4709 (2013.01); G01N 2800/2821 (2013.01);
Abstract

The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (Aβ N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of Aβ N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.


Find Patent Forward Citations

Loading…